Inari Medical (NARI) Projected to Post Quarterly Earnings on Wednesday

Inari Medical (NASDAQ:NARI) will likely be posting its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $160.70 million for the quarter.

Inari Medical Price Performance

NASDAQ:NARI opened at $79.97 on Tuesday. Inari Medical has a one year low of $36.73 and a one year high of $79.99. The business has a fifty day moving average price of $71.96 and a 200-day moving average price of $55.76. The firm has a market capitalization of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02.

Insider Buying and Selling at Inari Medical

In other news, Director William Hoffman sold 60,000 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $55.66, for a total transaction of $3,339,600.00. Following the transaction, the director now owns 441,233 shares of the company’s stock, valued at approximately $24,559,028.78. The trade was a 11.97 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Andrew Hykes sold 3,000 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $55.29, for a total value of $165,870.00. Following the completion of the sale, the chief executive officer now owns 439,310 shares of the company’s stock, valued at approximately $24,289,449.90. This represents a 0.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 263,000 shares of company stock worth $15,599,470 over the last 90 days. 10.60% of the stock is owned by insiders.

Analysts Set New Price Targets

NARI has been the topic of several recent research reports. Piper Sandler raised their price objective on Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 7th. Robert W. Baird reiterated a “neutral” rating and issued a $80.00 price target (down from $81.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Oppenheimer initiated coverage on shares of Inari Medical in a research note on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 price objective for the company. Baird R W cut shares of Inari Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 7th. Finally, Canaccord Genuity Group reiterated a “hold” rating and issued a $80.00 price target (up previously from $74.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Twelve analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Inari Medical presently has a consensus rating of “Hold” and an average price target of $68.00.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.